# FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-alectinib-as-adjuvant-treatment-for-alk-positive-non-small-cell-lun-28df138a09674f07
Kind: other · Impact: medium

## In brief

- On April 18, 2024, the FDA approved alectinib (Alecensa, Genentech) as adjuvant treatment following tumor resection.
- The approval covers patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
- Eligibility depends on the ALK-positive status being detected by an FDA-approved test.

## Why it matters

It extends alectinib from advanced disease to use after surgical removal of the tumor in ALK-positive NSCLC, a change that affects how patients in this setting may be treated.

## Timeline

- 2024-04-18: FDA approved alectinib as adjuvant treatment following tumor resection in ALK-positive NSCLC

## Coverage

- [FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer](http://www.fda.gov/drugs/cancer-approvals/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer) — What's New: Drugs RSS Feed, 2026-11-07

Tags: oncology, lung-cancer, alectinib, drug-approval, fda

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science